Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Aspira Womens Health Inc is transforming women's health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. OVA1 plus combines its FDA-cleared products OVA1 and OVERA to detect the risk of ovarian malignancy in women with adnexal masses. ASPiRA GenetiX testing offers both targeted and a more comprehensive genetic testing options with a gynecologic focus. Its focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection, and optimize treatment.
Austin, TX, 78738